This agreement grants Synthego a global license to manufacture and distribute AstraZeneca’s novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9, to the worldwide research community.

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the company’s drug candidate TCP-25 for the treatment of the severe disease Epidermolysis Bullosa (EB).

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.

Before Christmas Finnish Combinostics announced that it has entered an agreement with the Swedish company SyntheticMR where SyntheticMR will acquire all shares in Combinostics.

Capitainer plays a key role in the international AIR project (Artificial Intelligence Radiology) aimed at improving the diagnostics and monitoring of lung diseases.

The company has been granted a US patent for its SiPore platform technology.

The U.S. Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosing.

Elicera Therapeutics’ drug candidate ELC-100 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic neuroendocrine tumors.

BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology. 

Unfortunately genes do matter when it comes to obesity, but knowledge about these genes and how they work are key to improving treatment and prevention.

Anna Falk, Head of Lund University’s Center for Advanced Therapies (LU-ATMP) and principal researcher of the Department of Neuroscience at Karolinska Institutet (KI) shares insights into her research, her multi-faceted job, and her vision for the future of neuroscience. Anna Falk is a molecular biologist with a PhD in neural stem cells and adult neurogenesis. […]

An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular Cell, the team mapped structural alterations in cellular proteins during the aging process and, in the process, identifying new ways aging impacts how cells hum […]